Effects of fetal exposure to maternal chemotherapy

Pediatric Drugs

Volumn 15, Issue 5, 2013, Pages 329-334

  Dekrem, Jana ^a   Van Calsteren, Kristel ^a   Amant, Frédéric ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84885630023     PISSN: 11745878     EISSN: 11792019     Source Type: Journal    
DOI: 10.1007/s40272-013-0040-6     Document Type: Review

References (41)

1. Pavlidis NA. Coexistence of pregnancy and malignancy. Oncologist. 2002;7(4):279-87.
2. Walton JR, Prasad MR. Obstetric and neonatal outcomes of cancer treated during pregnancy. Clin Obstet Gynecol. 2011;54(4):567-73.
3. Van Calsteren K, Heyns L, De Smet F, et al. Cancer during pregnancy: an analysis of 215 patients emphasizing the obstetrical and the neonatal outcomes. J Clin Oncol. 2010;28(4):683-9.
4. Luis SA, Christie DR, Kaminski A, et al. Pregnancy and radiotherapy: management options for minimising risk, case series and comprehensive literature review. J Med Imaging Radiat Oncol. 2009;53(6):559-68.
5. Van Calsteren K, Verbesselt R, Beijnen J, et al. Transplacental transfer of anthracyclines, vinblastine, and 4-hydroxy-cyclophosphamide in a baboon model. Gynecol Oncol. 2010;119(3):594-600.
6. Arnon J, Meirow D, Lewis-Roness H, et al. Genetic and teratogenic effects of cancer treatments on gametes and embryos. Hum Reprod Update. 2001;7(4):394-403.
7. Cardonick E, Iacobucci A. Use of chemotherapy during human pregnancy. Lancet Oncol. 2004;5(5):283-91.
8. Ebert U, Loffler H, Kirch W. Cytotoxic therapy and pregnancy. Pharmacol Ther. 1997;74(2):207-20.
9. De Santis M, Di Gianantoni E, Straface G, et al. Ionizing radiations in pregnancy and teratogenesis: a review of literature. Reprod Toxicol. 2005;20(3):323-9.
10. Kal HB, Struikmans H. Radiotherapy during pregnancy: fact and fiction. Lancet Oncol. 2005;6(5):328-33.
11. Amant F, Van Calsteren K, Halaska MJ, et al. Gynecologic cancers in pregnancy: guidelines of an international consensus meeting. Int J Gynecol Cancer. 2009;19(Suppl 1):S1-12.
12. Isaacs RJ, Hunter W, Clark K. Tamoxifen as systemic treatment of advanced breast cancer during pregnancy: case report and literature review. Gynecol Oncol. 2001;80(3):405-8.
13. Amant F, Loibl S, Neven P, et al. Breast cancer in pregnancy. Lancet. 2012;379(9815):570-9.
14. Rasmussen SA. Human teratogens update 2011: can we ensure safety during pregnancy? Birth Defects Res A Clin Mol Teratol. 2012;94(3):123-8.
15. Azim HA Jr, Azim H, Peccatori FA. Treatment of cancer during pregnancy with monoclonal antibodies: a real challenge. Expert Rev Clin Immunol. 2010;6(6):821-6.
16. Azim HA Jr, Metzger-Filho O, de Azambuja E, et al. Pregnancy occurring during or following adjuvant trastuzumab in patients enrolled in the HERA trial (BIG 01-01). Breast Cancer Res Treat. 2012;133(1):387-91.
17. Makol A, Wright K, Amin S. Rheumatoid arthritis and pregnancy: safety considerations in pharmacological management. Drugs. 2011;71(15):1973-87.
18. Decker M, Rothermundt C, Hollander G, et al. Rituximab plus CHOP for treatment of diffuse large B-cell lymphoma during second trimester of pregnancy. Lancet Oncol. 2006;7(8):693-4.
19. Chakravarty EF, Murray ER, Kelman A, et al. Pregnancy outcomes after maternal exposure to rituximab. Blood. 2011;117(5):1499-506.
20. Shapira T, Pereg D, Lishner M. How I treat acute and chronic leukemia in pregnancy. Blood Rev. 2008;22(5):247-59.
21. Vandenbriele C, Vassou A, Pentheroudakis G, et al. Hematologic malignancies in pregnancy. In: Antica M, editor. Acute leukemia: the scientist's perspective and challenge. New York: InTech; 2011. p. 371-90.
22. Eskander RN, Tarsa M, Herbst KD, et al. Chronic myelocytic leukemia in pregnancy: a case report describing successful treatment using multimodal therapy. J Obstet Gynaecol Res. 2011;37(11):1731-3.
23. Yazdani BP, Matok I, Garcia BF, et al. A systematic review of the fetal safety of interferon alpha. Reprod Toxicol. 2012;33(3):265-8.
24. Gedeon C, Koren G. Designing pregnancy centered medications: drugs which do not cross the human placenta. Placenta. 2006;27(8):861-8.
25. Garland M. Pharmacology of drug transfer across the placenta. Obstet Gynecol Clin N Am. 1998;25(1):21-42.
26. Syme MR, Paxton JW, Keelan JA. Drug transfer and metabolism by the human placenta. Clin Pharmacokinet. 2004;43(8):487-514.
27. Ceckova-Novotna M, Pavek P, Staud F. P-glycoprotein in the placenta: expression, localization, regulation and function. Reprod Toxicol. 2006;22(3):400-10.
28. Gaillard B, Leng JJ, Grellet J, et al. Transplacental passage of epirubicin [article in French]. J Gynecol Obstet Biol Reprod (Paris). 1995;24(1):63-8.
29. Grohard P, Akbaraly JP, Saux MC, et al. Transplacental passage of doxorubicin [article in French]. J Gynecol Obstet Biol Reprod (Paris). 1989;18(5):595-600.
30. Heyns L, Van Calsteren K, Han SN, et al. Review: chemotherapy during pregnancy. Belgian J Hematol. 2011;2(3):101-6.
31. Van Calsteren K, Verbesselt R, Van Bree R, et al. Substantial variation in transplacental transfer of chemotherapeutic agents in a mouse model. Reprod Sci. 2011;18(1):57-63.
32. Gralla RJ, Osoba D, Kris MG, et al. Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. American Society of Clinical Oncology. J Clin Oncol. 1999;17(9):2971-94.
33. Van Calsteren K, Verbesselt R, Ottevanger N, et al. Pharmacokinetics of chemotherapeutic agents in pregnancy: a preclinical and clinical study. Acta Obstet Gynecol Scand. 2010;89(10):1338-45.
34. Wapner RJ, Sorokin Y, Mele L, et al. Long-term outcomes after repeat doses of antenatal corticosteroids. N Engl J Med. 2007;357(12):1190-8.
35. Avilés A, Neri N. Hematological malignancies and pregnancy: a final report of 84 children who received chemotherapy in utero. Clin Lymphoma. 2001;2(3):173-7.
36. Hahn KM, Johnson PH, Gordon N, et al. Treatment of pregnant breast cancer patients and outcomes of children exposed to chemotherapy in utero. Cancer. 2006;107(6):1219-26.
37. Amant F, Van Calsteren K, Halaska MJ, et al. Long-term cognitive and cardiac outcomes after prenatal exposure to chemotherapy in children aged 18 months or older: an observational study. Lancet Oncol. 2012;9:256-64.
38. Voigt B, Pietz J, Pauen S, et al. Cognitive development in very vs. moderately to late preterm and full-term children: can effortful control account for group differences in toddlerhood? Early Hum Dev. 2012;88(5):307-13.
39. van Baar AL, Vermaas J, Knots E, et al. Functioning at school age of moderately preterm children born at 32 to 36 weeks' gestational age. Pediatrics. 2009;124(1):251-7.
40. Mulder EJ, Robles de Medina PG, Huizink AC, et al. Prenatal maternal stress: effects on pregnancy and the (unborn) child. Early Hum Dev. 2002;70(1-2):3-14.
41. Van den Bergh BR, Mennes M, Stevens V, et al. ADHD deficit as measured in adolescent boys with a continuous performance task is related to antenatal maternal anxiety. Pediatr Res. 2006;59(1):78-82.